Sign In
Buy CTSO
$0.489
+0.0090 (+1.88%)
At Close: Jun 03, 2026
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
07:00am, Friday, 26'th Apr 2024
PRINCETON, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi
PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi
CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript
10:24pm, Thursday, 14'th Mar 2024
CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
04:39pm, Thursday, 14'th Mar 2024
STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 CytoSorbents intends to submit DrugSorb-ATR for regulatory a
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
07:00am, Wednesday, 06'th Mar 2024
PRINCETON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
07:00am, Thursday, 08'th Feb 2024
PRINCETON, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usin
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
07:40pm, Tuesday, 30'th Jan 2024
NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are a
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
07:55pm, Monday, 22'nd Jan 2024
NEW YORK , Jan. 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
07:15am, Wednesday, 17'th Jan 2024
CytoSorb Blood Purification Results in Significant Decrease in Organ Failure and Dysfunction in Groundbreaking Heart Transplant Randomized Controlled Trial
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
11:45am, Sunday, 14'th Jan 2024
NEW YORK , Jan. 14, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
11:15am, Saturday, 06'th Jan 2024
NEW YORK , Jan. 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors ar
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
01:08pm, Friday, 29'th Dec 2023
NEW YORK , Dec. 29, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
07:00am, Thursday, 28'th Dec 2023
PRINCETON, N.J., Dec. 28, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usin
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
09:15am, Wednesday, 13'th Dec 2023
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usin
Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript
10:06pm, Thursday, 09'th Nov 2023
Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript
